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Abstract
Kaposi's sarcoma-associated herpesvirus (KSHV) is the most recently discovered human
herpesvirus, first isolated and identified from a Kaposi's sarcoma lesion in 1994. It is the
etiological agent of Kaposi's sarcoma, a vascular lesion that is the predominant cancer among
AIDS patients. KSHV is also the primary etiological agent of two B-cell lymphomas, primary
effusion lymphoma and multicentric Castleman's disease. KSHV can exist in either a lytic phase,
in which the viral DNA is actively replicated and virions are assembled, or in a latent phase, in
which the viral genome is tethered to the host chromosome via protein–protein interactions. The
lytic cycle generally occurs following primary infection, and within 72–96 h in most cell types, the
virus enters the latent state. Reactivation from latency also leads to the intiation of the lytic cycle,
which is necessary for virus propagation and survival in the host. Several KSHV proteins have
been implicated in modulation of the host immune response to viral infection. This article
summarizes recent discoveries involving the innate immune response to KSHV infection.
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Kaposi's sarcoma-associated herpesvirus (KSHV) was identified by Chang and Moore in
1994 [1]. KSHV, also classified as human herpesvirus-8, is a dsDNA virus and a member of
the Herpesviridae family, and the γ-herpesvirus subfamily. The host cell range of KSHV
includes endothelial cells, B cells, monocytes, hematopoietic progenitor cells and dendritic
cells [2–6]. In each of these cell types, the virus primarily exists in the latent state, where the
viral genome is tethered to the host chromosome via the latency-associated nuclear antigen
[7–9]. In a latent infection, KSHV exists in a dormant state and persists for the lifetime of
the host. During latency, the viral genome persists in an episomal state, attached to host
chromosomes via latency-associated nuclear antigen's interactions with histones [7–9].
There are typically only a subset of viral genes that are actively transcribed during latency.
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By contrast, upon primary de novo infection of the host cell, the virus undergoes lytic
replication for approximately 72–96 h, prior to the establishment of latency [10]. The lytic
cycle is regulated by the expression of the master viral regulator open reading frame
(ORF)50/RTA [11]. During the lytic cycle, the viral genome is actively replicated and
progeny virions are assembled and released into the surrounding area where they can infect
neighboring cells. In addition to primary infection, KSHV undergoes lytic replication
following reactivation from the latent state. Environmental stresses such as superinfection
with another virus [12] and chemical treatment with 12-O-tetradecanoyl-phorbol-13-acetate
[13] can lead to lytic reactivation and the initiation of the lytic cycle.
Kaposi's sarcoma-associated herpesvirus is restricted to humans and its prevalence is
geographically defined. For example, KSHV is endemic in some regions of Africa [14–16].
In immune-suppressed individuals such as transplant patients or HIV-infected individuals,
KSHV-associated malignancies are increased. In fact, Kaposi's sarcoma is the leading cause
of cancer in HIV-infected individuals (reviewed in [17]).
The virus contains 84 ORFs and more than 20 viral proteins have been identified that are
capable of modulating proteins and/or pathways of the host immune system [18]. The large
number of viral genes dedicated to modulation of the host immune system indicates that
immune evasion is a necessity for this virus, and that immune modulation is critical for
maintaining the virus in a hidden, latent state.
The KSHV gene encodes a large number of viral genes with homology to cellular genes,
particularly ones that are involved in the host response to infection. KSHV also encodes a
large number of genes that mimic cellular genes, either in sequence and/or function.
Innate immunity is the body's first line of defense against invading pathogens and is often
sufficient in fighting off primary infection. Toll-like receptors (TLRs), RIG-I-like receptors
(reviewed in [19]) and nucleotide-binding domain leucine-rich repeat-containing receptors
(reviewed in [20]) are pathogen sensors involved in innate immunity [21]. Type I interferon
(IFN) is one of the critical defenses against invading pathogens. Activation of the IFN
response can lead to the antiviral state, which is characterized by apoptosis, degradation of
host cell RNA, a halt in protein processing and increased antigen presentation [22]. The
purpose of the antiviral state is to control the ability of the invading pathogen to replicate
and reduce its ability to spread, leading to the eventual elimination of the pathogen.
Toll-like receptors
Toll-like receptors are one of the first lines of defense for the innate immune system. They
recognize invading pathogens (bacteria, viruses and fungi) and trigger signaling cascades,
which lead to the activation of type I IFN, NF-κB and many other proinflammatory
cytokines. Human TLRs were first identified as homologs of the Toll proteins from
Drosophila. TLRs are classified as pattern recognition receptors, as they recognize invading
pathogens [23,24]. Currently, there are ten identified human TLRs. TLRs are
transmembrane proteins with an immunoglobulin-like extracellular domain and an
intracellular domain that contains a Toll/IL-1 receptor domain. TLRs trigger specific cell
signaling cascades [25]. TLRs contain 21–25 leucine-rich repeats in their extracellular
domains, which are responsible for recognition and binding to pathogen-associated
molecular patterns on the surface of the incoming pathogen [26]. However, not all TLRs are
expressed at the cell surface. TLR3, -7, -8 and -9 are all expressed in intracellular
compartments, primarily the endosome [27,28].
Recent research has identified TLR2, -3, -4, -7, -8, and -9 as being involved in the
recognition of viruses through binding of either RNA, DNA or viral glycoproteins [27,28].
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Two of the endosomal TLRs, TLR3 and -7, have been shown to be activated by RNA. TLR3
recognizes both ssRNA and dsRNA, while TLR7 recognizes ssRNA [23,29–34]. There are
two pathways that TLRs use for signaling, one being dependent on the adaptor protein
MyD88 and the other being a MyD88-independent pathway [24,27]. All TLRs signal
through the MyD88-dependent pathway with the exception of TLR3 and -4. TLR4 is
capable of signaling in a MyD88-independent or -dependent manner, while TLR3 strictly
signals via a MyD88-independent pathway [35]. The TLR3 adaptor protein is TRIF which
initiates the TLR3 signaling cascade upon binding to TLR3 [36].
The role of TLRs during primary infection
Currently, there are two reports implicating a role for TLRs during KSHV infection. We
published the first observation that TLR activation occurs upon infection of monocytes with
KSHV [37]. In both a monocytic leukemia cell line (THP-1) and primary human monocytes,
KSHV infection resulted in upregulation of TLR3 expression (mRNA and protein) and
downstream components of the TLR3 pathway, including IFN-β1 and the chemokine
CXCL-10 (IP-10). Knockdown of TLR3 prior to KSHV infection significantly reduced the
activation of TLR3 and its downstream effectors (Figure 1).
Lagos et al. demonstrated that upon primary infection of endothelial cells, TLR4 expression
was suppressed and that this repression allowed KSHV to escape the innate immune
response [38]. They also showed that cells lacking TLR4 were more susceptible to KSHV
infection and that activation of TLR4-protected cells from infection [38]. They identified the
KSHV viral proteins: viral G protein-coupled receptor and viral interferon regulatory factor
(IRF)-1, both of which are viral homologs of cellular G protein-coupled receptor and IRF-1,
respectively, as inhibiting TLR4 expression following infection (Figure 1).
Much more study is warranted on the effects of KSHV infection on the TLR pathway.
Considering that the TLR expression profile varies from cell to cell, and that KSHV is tropic
for different cell types, it would be interesting to determine whether a common or different
TLR is modulated in different cell types upon primary infection with KSHV. TLR3 is
known to be expressed in the following cell types: monocytes, macrophages, dendritic cells,
human fibroblasts and endothelial cells, several of which are tropic for KSHV (reviewed in
[39]).
The role of TLRs during reactivation
Owing to the fact that KSHV exists primarily in the latent state, reactivation is vital for the
survival and spread of the virus. However, not much is known about reactivation and the
activation of the innate immune response. Innate immunity is driven by primary infection of
a pathogen, and individuals with an established KSHV infection are those who have already
experienced primary infection. Our group recently reported that activation of the innate
immune response can lead to reactivation of KSHV from latency.
Gregory et al. showed that TLR7/8 and IRF-7 play important roles in the reactivation of
KSHV from latency [12]. Stimulation of TLR7/8 in KSHV latently infected primary
effusion lymphoma, either by synthesized agonist (poly-Uridine) or by infection with a
biologically relevant pathogen, vesicular stomatitis virus, a known activator of TLR7 and -8
[40]), led to viral reactivation and progeny virion production (Figure 1). In addition, a
dominant negative IRF-7 mutant protein significantly inhibited latent primary effusion
lymphoma cells from being able to reactivate and produce virus after TLR7/8 stimulation
[12]. If TLR signaling, typically responsible for recognition of new incoming pathogens, can
also lead to the reactivation of a latent viral reservoir, then this represents a physiological
stimulus that can lead to viral reactivation. It also represents a new role for TLR stimulation
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in the context of KSHV and suggests that KSHV takes advantage of a TLR-mediated ‘death’
signal to reproduce itself and leave a cell that is fated to die [12]. This ensures persistence
and spread of KSHV in the human population.
The above studies suggest that KSHV has the ability to both suppress and evade the host
response during a primary infection in order to establish latency. In addition, in the context
of viral latency, it can also use the activation of the innate immune response to invading
pathogens to reactivate and persist in the host. Thus, KSHV responds to environmental
conditions by switching between its latent and lytic phases, thereby ensuring lifetime
persistence in the infected host.
Complement system
The complement system is also a component of the innate immune response and similar to
the TLRs, can respond to both bacterial and viral infection. There are three different
pathways through which the complement system activates particular proteins that ultimately
lead to the formation of the membrane attack complex [41]. The membrane attack complex
is responsible for punching holes in the invading pathogen (bacteria or virus), resulting in
killing of the pathogen, and ending the infection. Complement can also act by opsonization,
which involves depositing one of two complement proteins (either C3b or C4b) on the
surface of the invading pathogen. Opsonization leads to increased phagocytosis and humoral
response to infection [42].
Kaposi's sarcoma-associated herpesvirus has developed a mechanism by which the virus can
interfere with the activity of the complement system. The KSHV ORF4 gene encodes a
homolog of the human complement control family of proteins, referred to as KSHV
complement control protein (KCP) [43,44]. KCP is expressed during the lytic cycle and
contains alternative splice sites, which results in the production of three protein isoforms.
Each of these isoforms contains the conserved SCR sequence, the sequence common to each
of the human complement control proteins, giving these viral homologs the ability to
modulate the complement system. KCP manipulates the complement system to ensure the
survival of the virus and reduce the chance of viral killing via any host complement proteins.
KCP has been shown to inhibit the complement response in three ways: it enhances the
decay of C3 convertase; it prevents depositing of C3b on the surface of sensitized cells,
preventing opsonization; and KCP acts as a cofactor for factor I-mediated inactivation of
C3b and C4b (Figure 2) [43–46]. By enhancing C3 decay, KCP inhibits the complement
pathway and the formation of the membrane attack complex, and prevention of opsonization
allows infected cells to escape phagocytosis and degradation. Both of these outcomes are
positive for the virus and allow the virus to escape a key element of the innate immune
system, presumably making the task of establishing latency much easier to accomplish
following primary infection.
Viral IRFs
Kaposi's sarcoma-associated herpesvirus encodes four proteins with homology to members
of the human IRF protein family (reviewed in [47]). Cellular IRFs are transcription factors
that can transactivate type I IFN genes and many other cytokines and chemokines.
Considering their role in transcriptional activation of the IFN response and the cytokine/
chemokine response, the IRFs are a critical element of the innate immune response
(reviewed in [48]). Consequently, it is not surprising that they are a target of several KSHV
genes and that their functions are modified in a KSHV-infected cell. The vIRFs are largely
responsible for modulation of cellular IRFs; however, several other KSHV proteins have
also been identified as modulators of the cellular IRFs.
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Viral IRF-1, encoded by the K9 gene in KSHV, has several functions in the innate immune
response. vIRF-1 has been identified as a negative regulator of the type I IFN response,
accomplishing this via binding to the p300 protein, a transcriptional coactivator that along
with IRF-1 and IRF-3 activates several genes critical in the innate immune response [49–
51]. By binding to p300, vIRF-1 prevents p300 association with IRF-1 or -3 and therefore
inhibits the transcriptional activity of IRF-1 and -3 (Figure 1). This serves to greatly dampen
the innate immune response, possibly creating a more favorable environment for the
establishment of latency. vIRF-1 has also been shown to bind cellular IRF-1, -3 and -7;
however, only IRF-3-mediated transcription has been shown to be inhibited due to vIRF-1
binding to p300 [51]. vIRF-1 also inhibits IRF-1-mediated transcription, but does so without
binding to IRF-1 or competing with IRF-1 for DNA binding [52]. However, the same group
has also published that vIRF-1 may not contribute as greatly to innate immune evasion, in
vivo, owing to its short half-life during KSHV infection [53]. All of the aforementioned
studies were performed in the presence of overexpressed vIRF-1. vIRF-1 has also been
shown to inhibit TGF-β signaling [54].
Viral IRF-2 is encoded by the K11 and K11.1 genes and has also been shown to play a role
in the evasion of the innate immune response. Full-length vIRF-2 has been implicated in the
inhibition of the IFN response [55], although the exact nature of the inhibition is not yet
known. It was determined using an IFN-stimulated response element (ISRE) driven reporter
that IFN-α and -λ signaling could both be inhibited by vIRF-2 (Figure 1). vIRF-2 also
inhibited transactivation of this reporter via cellular IRF-1, indicating a role for IRF-1
inhibition by vIRF-2. Activation of an IFN-β reporter by IRF-1 or -3 was also blocked by
expression of vIRF-2, implicating a role for vIRF-2 in the blockage of IRF-1- and -3-
mediated IFN signaling [55]. Recently, a novel role for vIRF-2 was reported, showing that it
can hinder the transactivation of cellular IRF-3, a vital component of type I IFN activation,
thereby inhibiting the antiviral response [56]. This study showed that in the presence of
caspase-3, vIRF-2 expression enhanced caspase-3 degradation of IRF-3.
Viral IRF-3, a viral protein encoded by the K10.6/10.5 locus, has been reported to inhibit
IRF-7-mediated induction of the IFN signaling pathway [57]. It was determined that vIRF-3
was able to accomplish this inhibition by preventing IRF-7 from binding to DNA,
consequently blocking production of normal levels of IFN (Figure 1). vIRF-3 can also block
NF-κB signaling, a key mediator of the innate response [58]. NF-κB activates the
transcription of numerous cytokines and chemokines, as well as type I IFN. In 2000,
Lubyova et al. reported inhibition of both IRF-3- and -7-mediated activation of IFN-α and in
2004, the same group reported that vIRF-3 can stimulate IRF-3- and -7-mediated activation
of IFN-α, via its recruitment to the IFN-α promoter as a complex with IRF-3 and -7 [59,60].
Therefore, depending on the circumstances, vIRF-3 is capable of functioning either as a co-
activator or co-repressor of the IFN response.
Viral IRF-4 is the most recently discovered KSHV homolog to a cellular IRF. vIRF-4 was
demonstrated to interact with MDM-2, an E3 ubiquitin ligase that targets p53 for
proteasomal degradation (Figure 2) [61]. Activation of p53 often leads to apoptosis and
tumor suppression. Therefore, the degradation of p53 mediated by vIRF-4 would be
extremely beneficial to KSHV, allowing infected cells to escape p53-mediated apoptosis and
continue to persist in the host.
Additional viral immune modulatory genes
In addition to the vIRF proteins, several other KSHV proteins have been identified as being
important for controlling the host IFN response and helping KSHV avoid eliciting a strong
West and Damania Page 5













innate immune response. Several of these proteins also function similarly to the vIRFs in
that they target the cellular IRFs and inhibit their transactivation of IFN signaling.
Kaposi's sarcoma-associated herpesvirus ORF45, classified as an immediate early protein,
was shown to decrease the type I IFN response by inhibiting IRF-7 function (Figure 1). It
was demonstrated in vitro, and in the context of a viral infection, that ORF45 blocked
phosphorylation of IRF-7 and its accumulation in the nucleus [62,63]. This led to a
downregulation of the type I IFN response upon infection of cells with Newcastle Disease
virus, a known activator of type I IFN.
Open reading frame 50/RTA, the activator of viral transcription and the lytic cycle, has been
reported to modify IRF-7 function. Yu et al. showed that RTA can bind to IRF-7 and target
it for degradation (Figure 1) [62,64]. The E3 ligase activity of RTA targets IRF-7 for
ubiquitination, and eventual degradation by the proteasome. This mechanism is yet another
way for KSHV to manipulate the innate immune response, and evade detection by the host
cell, making the establishment of latency much easier.
Viral Bcl-2, a protein encoded by the ORF16 locus, is the viral homolog of members of the
cellular Bcl-2 family of proteins. Cellular Bcl-2 family members can have either
antiapoptotic activity (Bcl-2 or Bcl-xL) or proapoptotic activity (BAK, BAD and BAX)
[65]. KSHV vBcl-2 can bind peptide sequences from three proapoptotic death proteins,
BAK, BAX and BAD [66]. However, another paper reported contradictory results,
concluding that vBcl-2 inhibited apoptosis without binding to BAX or BAK [67].
Clarification of how vBcl-2 aids in evading the apoptotic response after infection is needed,
but it is clear that vBcl-2 plays a role in inhibiting this facet of the innate immune response.
More recently, vBcl-2 has been implicated in the modulation of autophagy, a cell survival
mechanism in which the cell sequesters cytoplasmic components in response to viral
infection, and delivers them to the lysosome for degradation [68,69]. In 2005, Pattingre
demonstrated that KSHV vBcl-2 can inhibit the process of autophagy by binding to
Beclin-1, a protein which promotes autophagy and inhibits tumorigenesis (Figure 2) [70].
Inhibition of both apoptosis and autophagy, two of the primary means by which an infected
host cell is able to prevent viral spread and tumorigenesis, is key for the survival of KSHV
and its persistence in the host.
Kaposi's sarcoma-associated herpesvirus also encodes a viral FLICE inhibitory protein
(K13), known as vFLIP. Reports have shown that vFLIP also plays a role in immune
modulation including the activation of NF-κB and also the upregulation of IL-8, both key
players in the immune response [71,72]. Recently, vFLIP has also been shown to modulate
autophagy [73]. Kaposin, encoded by the K12 gene, also modulates cytokine expression by
stabilizing cytokine mRNA, which may be important for disease progression and virus
survival [74]. KSHV also encodes several viral miRNAs, which perform a myriad of
different functions. In particular, KSHV miRNA 12–11 (mirK11) is an ortholog of cellular
miR-155 and has been shown to downregulate BACH-1 and Fos [75,76] O'Connell et al.
have previously reported that cellular miR-155 is a TLR-responsive and IFN-β-inducible
miRNA. They showed that cellular miR-155 served as a common target of inflammatory
cytokines [77]. Thus, it is plausible that KSHV mirK11 may also play a similar role.
Direct IFN effects
Since the IFN response is probably the most critical aspect of the innate immune response, it
is not surprising that KSHV can directly modulate type I IFN responses. Multiple reports
have shown that KSHV infection can lead to suppression of the IFN-response and also to
suppression of several IFN responsive elements. Targeting the IFN response is a common
theme among human herpesviruses, specifically downregulation of the type I IFN response.
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Several recent studies have shown that KSHV is not the only human herpesvirus that targets
the IFN system in order to aid its goal of achieving latency. Paladino et al. discuss multiple
mechanisms by which HSV-1 downregulates the IFN response [78]. Recently, for HSV-2 a
similar result was observed, IFN-α and -β were both present at decreased levels in biopsy
samples from HSV-2-infected lesions [79]. In addition, an Epstein–Barr virus-encoded
protein, LMP1, can decrease type I IFN [80]. Overall, KSHV shows strong similarities to
other human herpesviruses in its ability to evade the host innate immune response and a
common target amongst the herpesviruses is the type I IFN response.
In a comprehensive study, investigating KSHV infection of endothelial cells, B cells and
human fibroblasts [81], there were a myriad of IFN-responsive genes whose transcription
was upregulated following KSHV infection. However, direct activation of type I IFN was
not shown. This could be caused by viral products that suppress the IFN response.
Interestingly, a recent paper has identified a 100 base pair repeat region in MHV-68 that is
required for activation of IFN-α [82]. They also identified a colinear region in the KSHV
genome and after transfection into 293 cells determined that this region in KSHV also
stimulates IFN-α production. It is possible that the overwhelming number of viral genes
dedicated to shutting down the IFN response masks this effect in a live virus infection;
however, more research of this repeat region could yield very informative results regarding
the activation of the IFN response after KSHV infection.
Viral IL-6, the viral homolog of human IL-6, has been reported to inhibit the IFN response
by a unique mechanism [83]. The vIL-6 promoter contains an ISRE that is specifically
activated by IFN-α treatment. However, it was also shown that vIL-6 could prevent the
binding of the IFN transcriptional activator, IFN-stimulated gene factor-3 to ISRE-
containing probes, indicating a mechanism by which vIL-6 could negatively regulate the
IFN response in a virus infected cell (Figure 2). This is a unique mechanism by which the
cells' natural IFN response is used against itself, resulting in the activation of a viral protein
(vIL-6) that, in turn, shuts down the host IFN response [83]. It is possible that a very small
IFN response is needed to activate vIL-6; however, only a small increase in vIL-6 may be
enough to lead to a significant reduction in the IFN response. This is just one more avenue
by which KSHV modulates the cellular innate immune response to minimize detection.
Yet another mechanism has been reported by which KSHV downregulates the type I IFN
response, in this case specifically the IFN-β response. The viral protein K-bZIP, encoded by
K8, is able to suppress IFN-β production by binding to the promoter within the IRF3 binding
site in the IFN-β gene [84]. It binds specifically to the positive regulatory domain I/III
region, the region which is normally occupied by IRF3 to promote IFN-β gene transcription.
So far, we have only discussed the inhibition of the IFN response by KSHV, whether it be
direct inhibition, or one mediated by inhibition of a transcription factor. Recently, however,
our lab has reported that in response to KSHV primary infection, human monocytic
leukemia (THP-1) cells show a significant increase in IFN-β transcription and a concomitant
increase in secreted IFN-β [37]. This increase in IFN was observed at 16 h postinfection but
declined shortly thereafter [West JA, Damania B, Unpublished Observations]. This indicates
that a small, short-lived innate immune response may be necessary for the virus to enter
latency. In a situation in which no innate immune response was present, there would likely
be rampant lytic replication that would be detrimental to the host. Without an innate immune
response, there would not be a strong trigger for an adaptive immune response, through
which the host could eradicate the virus. Thus, the activation of innate immunity may
actually aid KSHV to establish latency and evade the subsequent wave of adaptive
immunity.
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Another aspect of the innate immune response is cell killing, usually mediated by natural
killer (NK) cells. NK cells are able to kill infected cells in the absence of antigen
presentation. NK cells accomplish this via specific surface receptors, which are activated
upon binding their ligands. The viral gene K5, also known as MIR2, has been shown to play
a key role in the ability of KSHV to avoid the cell killing potential of NK cells. Two reports
have shown that K5 downregulates four separate molecules that are specific to the cell
surface receptors expressed by NK cells. Coscoy and Ganem, along with Ishido et al.,
demonstrated that K5 reduced the expression of ICAM-1 and B7-2, both of which normally
activate NK cell-mediated killing when expressed on the cell surface (Figure 2) [85,86]. K3/
K5 have also been shown to reduce surface expression of MHC class I chains, which allows
KSHV to evade recognition by the host immune system, in this case specifically recognition
by cytotoxic T lymphocytes, which typically recognize viral peptides presented on the
surface of infected cells (Figure 2) [87]. K3 and K5, also known as modulators of immune
recognition (MIR1 and -2), regulate expression of these cell surface markers via
ubiquitination, which leads to their endocytosis [88]. In addition, K5 was also shown to be
responsible for the downregulation of two more NK cell receptor ligands, MICA and MICB
(MHC class I-related chains A and B), both of which normally trigger the cell killing
response of NK cells, via binding to two NK cell specific surface receptors, NK2GD and
NKp80, respectively [89]. K5 induces the internalization of MICA/B, via ubiquitination of
lysine residues on the cytoplasmic tails of MICA/B [18,89]. The reduction in expression of
these ligands is vital for KSHV to avoid NK cell-mediated lysis, and provides yet another
route by which KSHV can escape the innate immune response. K3 and K5 have also been
shown to inhibit the production of IFN-γ by downregulating the expression of γ-interferon
receptor 1 (IFN-γR1) [90]. This represents another aspect of the IFN response that can be
negatively regulated by KSHV upon infection.
Conclusion & future perspective
It is clear that one of the key components of the KSHV lifecycle is its ability to manipulate
the host innate immune response. It is also evident that the virus employs several different
strategies to accomplish this, such as the repression of host cellular transcription factors
IRF-1, -3 and -7, and IFN-stimulated gene factor-3, which leads to the disruption of the
innate immune response. KSHV infection can lead to stimulation of the innate immune
response and the virus can also respond to innate immune signals by reactivating and
replicating its genome, or making viral proteins that work to shut down the host innate
immune response.
The study of KSHV primary infection is critical for understanding the host innate immune
response to KSHV infection and the modulation of host responses by the virus. In order to
enter latency, the virus must avoid the detrimental consequences of innate immune
activation, and hence understanding how the latent state is established after primary
infection is key.
Another question relates to the activation of TLR signaling by KSHV. It has been reported
that KSHV encodes and packages 11 RNA molecules in the tegument of an infectious
particle [91]. Since TLR3 can respond to RNA, it is possible that upon infection and virus
entry, the packaged RNA in the tegument is responsible for TLR3 stimulation. Another
possibility is that a viral gene activates TLR3 once the genome reaches the nucleus early
after infection and that this leads to the upregulation of the TLR3 signaling pathway. Further
investigation of how exactly KSHV activates the TLR3 pathway would provide clues into
the role of TLR activation during primary KSHV infection.
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Elucidation of the roles of vIRF-3 and -4 are also important for determining the ability of
KSHV to modulate the innate immune response. At this point only one report on the role of
vIRF-4 has been published, and based on the evidence provided thus far for other KSHV
vIRFs, and the homology of vIRF-4 to -1 and -2, it is likely that vIRF-4 has additional
functions in the subversion/control of the innate immune response. Furthermore, vIRF-3 has
been reported to have both stimulatory and repressive activities on IRF-3- and -7-mediated
transcription of the IFN response [57–60]. Hence, there is much to be learned about the role
of this protein and its contribution to KSHV's ability to manipulate the host immune
response.
Viral Bcl-2 is another interesting viral protein that may be involved in innate immunity as it
relates to apoptosis and autophagy. Inhibition of both apoptosis and autophagy by vBcl-2
points to a critical role for vBcl-2 during both primary infection and reactivation. Further
study on the mechanism(s) by which vBcl-2 can inhibit these responses will provide
information about KSHV persistence in the host.
Almost all viruses induce some sort of type I or II IFN response upon primary infection, and
we reported that IFN-β is induced in monocytes as well as a monocytic leukemia cell line
(THP-1) after KSHV infection [37]. It is unclear if type I or II IFN responses are induced in
other cell types in response to KSHV infection. However, Naranatt et al. showed that a
number of IFN-inducible genes are activated upon KSHV infection [81]. Hence, the ability
of KSHV to induce IFN responses may depend on cell type and/or the multiplicity of
infection.
In summary, KSHV, with its myriad of immune evasion genes, is an excellent model system
for studying immune modulation of the host response to viral infection. This virus is able to
evade innate immune responses and enter a latent state for the lifetime of the host. Without
clearance of this virus, an infected individual is always at risk for viral reactivation and
KSHV-associated pathogenesis. Discovering the mechanisms that KSHV employs to evade
host innate and adaptive immune responses, and establish life-long latency, is paramount for
the development of future vaccines and therapeutics against this herpesvirus.
Executive summary
• Kaposi's sarcoma-associated herpesvirus (KSHV) is the leading cause of cancer
in HIV-infected individuals.
• KSHV has pirated multiple cellular genes to regulate/control the innate immune
response to primary infection.
Toll-like receptors
• Toll-like receptors (TLRs) recognize incoming pathogens and aid in the
initiation of the innate immune response.
• Multiple TLRs have been shown to be involved in virus recognition.
• TLR3 can be upregulated in response to KSHV infection, while TLR4 is
suppressed upon KSHV infection.
• Stimulation of TLR7/8 can lead to reactivation and production of infectious
KSHV virions from latently infected B cells.
Complement system
• The complement system is involved in recognition of invading pathogens.
Complement activation leads to:
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– Lysis of the pathogen via membrane attack complex
– Degradation via opsonization
• KSHV encodes a complement control protein, KCP, which can prevent both
opsonization and the formation of the membrane attack complex.
Viral interferon regulatory factors
• Viral interferon regulatory factors (IRFs) are homologs of the cellular IRF
family of proteins.
• Viral IRFs have been shown to interfere with the transcriptional activity of the
cellular IRFs, thereby inhibiting the host innate immune response, primarily the
type I IFN response.
• Viral IRF-4 can also inhibit apoptosis via degradation of p53.
Additional viral immune modulators
• Open reading frame 45 inhibits cellular IRF-7.
• Open reading frame 50 can induce IRF-7 degradation via ubiquitination.
• Viral Bcl-2 can inhibit proapoptotic death signals and is also an inhibitor of
autophagy.
• Viral IL-6 can inhibit the IFN response to KSHV infection.
• K-bZIP can suppress the IFN-β1 response to virus infection.
• K5 downregulates ligands that induce cell death via natural killer cells and also
downregulates MHC I molecules.
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Figure 1. Modulation of the Toll-like receptor pathway by Kaposi's sarcoma-associated
herpesvirus
After entry via endocytosis, KSHV stimulates TLR3, which leads to upregulation of
downstream cytokines such as CXCL-10 and IFN-β1 in monocytes, while KSHV can
downregulate the expression of TLR4 after endothelial cell infection. KSHV vGPCR along
with vIRF1 are responsible for this TLR4 inhibition. The KSHV ORF45 IE gene inhibits
IRF-7, while KSHV RTA targets IRF for degradation via ubiquitination. vIRF-1 binds CBP/
p300, inhibiting the transcription of cellular IRFs and the IFN response. vIRF-3 blocks the
activation of the IFN response by blocking IRF-7 binding to IFN promoters. vIRF-2 also
blocks the IFN response via inhibiting the transcription function of cellular IRFs. Finally, in
the context of latency, TLR7/8 stimulation with poly-(U)ridine or vesicular stomatitis virus,
leads to reactivation of latent KSHV and infectious virion production. IFN: Interferon; IRF:
Interferon regulatory factor; KSHV: Kaposi's sarcoma-associated herpesvirus; TLR: Toll-
like receptor; vGPCR: Viral G protein-coupled receptor; vIRF: Viral interferon regulatory
factor; VSV: Vesicular stomatitis virus.
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Figure 2. Kaposi's sarcoma-associated herpesvirus complement protein blocks two aspects of the
host complement response, opsonization and the membrane attack complex
K3/K5 block the expression of cell surface ligands ICAM-1 and B7-2, which activate NK-
mediated cell death. K5 also enhances the endocytosis of MHC class I molecules, which
inhibits recognition by CTLs. vIL-6 blocks ISGF-3 from binding the IFN promoter,
inhibiting the production of IFN. vBcl-2 binds the autophagy enhancement protein Beclin-1,
inhibiting the process of autophagy, a process involving autophagosomes, and lysosomes in
which cellular components are degraded by lysosomes. vIRF-4 can bind and stabilize
MDM-2, which in turn leads to the ubiquitination and subsequent degradation of p53 by the
proteasome.
CTL: Cytotoxic T lymphocyte; IFN: Interferon; ISGF: Interferon-stimulated gene factor;
ISRE: Interferon-stimulated response element; KSHV: Kaposi's sarcoma-associated
herpesvirus; NK: Natural killer; STAT: Signal transducer and activator of transcription;
vBcL: Viral Bcl; vIL: Viral IL; vIRF: Viral interferon regulatory factor.
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